过去一年，经济和资本市场向好，加上强化版财政整合计划渐见成果，香港公共财政状况改善较预期 快，提前由亏转盈。据预计，2025/2026年度综合账目将由原来预算约670亿港元赤字，转为录得29亿港 元盈余。 特区政府财政司司长陈茂波在预算案中提出一系列打造国际创新科技中心的措施，包括提速AI推动产 业化、建设北都国际创科新城、培育与壮大新兴产业等。 来源：新华社 新华社香港2月26日电 香港特区政府2026/2027财政年度财政预算案25日出炉。各界人士认为，预算案 主动对接国家"十五五"规划建议，从"AI（人工智能）+"和"金融+"两条主线推进，将进一步加强香港的 核心竞争力，增强经济动能，扎实推动香港经济提速增量。 香港特区立法会议员邱达根注意到，预算案将航天科技、具身智能等前沿领域纳入发展蓝图，展现特区 政府对新兴科技趋势的敏锐把握，以及全面对接国家"十五五"规划的决心。 香港科学院及香港青年科学院表示，预算案与国家"十五五"规划建议高度对接，同频发展，既能进一步 落实香港国际创新科技中心的定位，也能充分发挥香港背靠祖国、联通世界的独特优势，助力香港汇聚 全球顶尖研发团队与高端科技人才，让创科成为香港未来 ...

Core Viewpoint - The recent developments in Hong Kong's economic and financial landscape have garnered significant attention, with a notable increase in IPO activities and GDP growth projected for 2025, indicating a robust recovery and expansion trend since 2021 [2][3]. Group 1: IPO and Market Dynamics - In 2025, Hong Kong is expected to witness 119 IPOs, with a substantial increase in financing, leading the global market [2]. - The Hong Kong stock market has seen a record net inflow of southbound capital, reaching 1,404.84 billion HKD in 2025, marking a historical high since the launch of the Stock Connect program [2]. - The introduction of new IPO regulations by the Hong Kong Stock Exchange in August 2025 has improved the pricing and allocation mechanisms for new shares, while lowering the listing thresholds for "A+H" issuers [2][3]. Group 2: Capital Inflows and International Participation - Domestic capital is actively participating in the Hong Kong stock market for cross-border asset allocation, contributing to a cumulative net inflow of over 5.1 trillion HKD since the Stock Connect's inception [2]. - International capital is increasingly entering the Hong Kong market, driven by a weaker US dollar and global liquidity conditions, seeking safe returns [2][3]. - The majority of new companies established in Hong Kong in 2025 are engaged in import-export trade, wholesale, and retail, reflecting Hong Kong's status as an international trade and financial hub [4]. Group 3: Technological and Structural Developments - The listing rules for unprofitable biotech companies and specialized technology firms in Hong Kong have encouraged the growth of high-tech enterprises, leading to market valuation premiums [3]. - The Hong Kong government is prioritizing the development of an international innovation and technology center, supported by national policies aimed at enhancing technological self-reliance and productivity [5]. - The synergy between technology and finance is expected to drive structural upgrades in Hong Kong's economy, enhancing its competitiveness as an international financial center [5]. Group 4: Future Development Focus - Future national development priorities include promoting supply-side structural reforms, deepening demand-side reforms, and expanding high-level openness [6]. - Hong Kong is positioned to play a crucial role in enhancing national competitiveness in supply chains and participating in the Greater Bay Area market development [6]. - To achieve these goals, Hong Kong must strengthen its hard and soft power across various dimensions, including economic, industrial, and technological capabilities [6].

近日，浙江翼菲智能科技股份有限公司（以下简称"翼菲智能"）向港交所递交招股书，这是2025年6月首次递表失效后的第二次尝试。 | 編纂]項下的[編纂]總數目 : | 「編纂]股H股(視乎[編纂]行使與否而定) | | --- | --- | | [編纂]數目 : [编纂]股H股(可予[编纂]) | | | [編纂]數目 | 「編纂]股H股(可予[編纂]及視乎[編纂]行使 | | 與否而定) | | | 最高[編纂] : | 每股H股[編纂]港元,另加1%經紀佣金、 | | 0.0027％證監會交易徵費、0.00565%聯 | | | 交所交易費及0.00015%會財局交易徵 | | | 費(須於[編纂]時繳足,多繳股款將根 | | | 據最終定價予以退還) | | | 面值 : 每股H股人民幣[0.25]元 | | | [编纂] : . | | 在现金流方面，翼菲智能的表现同样不容乐观。2022-2024年，该公司经营活动现金流持续为负，累计净流出达2亿元以上。截至2024年底，该公司账上现金 及等价物仅剩2290万元，而计息银行借款却高达1.35亿元；资产负债比率从2022年的43.84%飙升至2024年末 ...

【财华社讯】12月25日，广东省地方金融管理局等10部门联合印发《广东省推动金融服务科技强省建设 工作方案》。方案提出，发挥多层次资本市场支持科技创新的关键枢纽作用。统筹运用多层次资本市场 各类工具支持科技型企业在"成长期—扩张期—成熟期"等不同阶段的发展。强化"三所一中心"协同机 制，支持各地市建立规范化、分层级、分产业的上市培育孵化体系，打造科技上市军团。引导科技型企 业适配沪深主板、科创板、创业板、北交所等各板块定位上市融资，鼓励未盈利科技型企业上市利用好 上海证券交易所科创板科创成长层、深圳证券交易所创业板第三套上市财务标准。引导科技型企业合理 用好境内外上市"两个市场、两种资源"，支持符合条件的生物医药企业与特专科技企业通过港股18A、 18C赴港上市融资。引导科技型企业综合运用股份、定向可转债等各类资本工具开展并购重组，围绕重 点产业强链、补链、延链，向研发端和市场端等产业链上下游延伸。夯实区域性股权市场"塔基"功能， 高质量建设"专精特新""科技创新"专板。 本文源自：财华网 ...

Core Insights - The Hong Kong IPO market has seen a significant presence of biopharmaceutical companies, with most listing under the HKEX Chapter 18A for unprofitable biotech firms, achieving strong first-day performance with many stocks rising over 100% [1] - The geographical distribution of these listings is concentrated, with 13 out of 19 biopharmaceutical companies coming from the Yangtze River Delta region, which includes 7 from Jiangsu, 4 from Zhejiang, and 2 from Shanghai [1] - The Yangtze River Delta contributes 30% of the national biopharmaceutical output, 30% of drug sales, and 70% of domestically produced Class 1 new drugs, with an industry value exceeding 1 trillion [1] - Additionally, 6 companies have listed under HKEX Chapter 18C for specialized technology firms, with 3 of these from the Guangzhou-Shenzhen area [1] - Market analysis suggests that as new first-tier cities enhance their IPO cultivation efforts, combined with the Hong Kong market's inclination towards specialized technology sectors, future mainland IPOs are expected to exhibit a "core leading, multi-point blossoming" trend [1] - Local governments are encouraged to align their local industry characteristics with the demands of the Hong Kong stock market [1]

Core Viewpoint - Livermore Securities has successfully underwritten the Hong Kong IPO of Dipu Technology, which recorded an oversubscription of over 7,500 times, raising more than HKD 270 billion, making it the most oversubscribed IPO in the Hong Kong special technology sector this year [1] Group 1 - The IPO of Dipu Technology has attracted significant interest from global long-term funds such as VanCapital, BlackRock, and Symmetry [1]

Core Viewpoint - The Hong Kong Stock Exchange (HKEX) has introduced a new policy called "Tech Company Special Line," which provides a confidential listing channel and lowers the threshold for specialized technology and biotechnology companies, attracting more tech firms to consider listing in Hong Kong [1][2]. Group 1: Target Audience - Applicable to specialized technology companies (e.g., AI, chips, new energy) and biotechnology companies (e.g., innovative drugs, medical devices), especially those in early stages or with non-commercialized products [3]. Group 2: Eligibility Criteria - Core thresholds include: - Industry attributes: Must belong to HKEX-defined "specialized technology" (Chapter 18C) or "biotechnology" (Chapter 18A) fields. - R&D investment: For specialized technology, R&D spending must account for ≥15% of total costs over the past three years; for biotechnology, core products must have passed Phase I clinical trials. - Commercialization stage: Companies can be unprofitable and have no revenue but must demonstrate technical feasibility and market potential (e.g., patents, letters of intent) [5]. Group 3: Application Process - Step 1: Determine eligibility using the self-assessment tool available on the HKEX website [6]. - Step 2: Submit a confidential application, including signing a Non-Disclosure Agreement (NDA) with HKEX [8]. - Step 3: Provide a "confidential version" of materials, ensuring compliance with format requirements [10]. - Step 4: The HKEX team will provide feedback within 30 days, focusing on technical feasibility and compliance [11]. Group 4: Specialized Services - One-on-one guidance from HKEX experts is available for free, covering listing rules and fundraising strategies [13]. - Qualified companies can benefit from a fast-track review process, reducing the review period to 30 days [14]. - Flexible equity design allows founders to retain control without additional proof of "innovation" [15]. Group 5: Common Pitfalls - Avoid vague technical descriptions; provide third-party certifications and endorsements [17]. - Ensure transparency in related-party transactions; disclose fair pricing evidence [20]. - Strengthen investor relations by involving independent investors and disclosing key investment terms [22]. Group 6: Post-Listing Compliance - Continuous compliance includes mandatory disclosures on commercialization progress and R&D milestones [22]. - Companies can maintain market value by issuing quarterly R&D updates and engaging with analysts [23]. - A green channel for fundraising allows specialized companies to issue new shares through a simplified process [24]. Group 7: Market Comparison - The article compares the listing requirements and processes of Hong Kong (Tech Company Special Line), A-shares (Sci-Tech Innovation Board), and U.S. stocks (NASDAQ), highlighting differences in profitability requirements, review periods, valuation levels, and disclosure pressures [25].

Core Viewpoint - The Hong Kong stock market has seen a significant shift in the IPO landscape for specialized technology companies, particularly those in AI, semiconductors, and autonomous driving, with no successful IPOs for 18C companies in 2025 despite initial enthusiasm in 2024 [1][9]. Group 1: Market Dynamics - In 2024, 18C specialized technology companies were highly sought after, but by 2025, the market has not seen any completed IPOs among the 12 companies that have submitted applications [1][9]. - The Hong Kong Stock Exchange implemented reforms on September 1, 2024, lowering the minimum market capitalization requirements for 18C companies, with commercialized companies' thresholds reduced from HKD 60 billion to HKD 40 billion, and non-commercialized companies from HKD 100 billion to HKD 80 billion [1][9]. Group 2: Company Performance - Three listed 18C companies have been active in secondary market financing, with Crystal Technology raising HKD 32.2 billion through two rounds of fundraising, significantly exceeding its IPO fundraising scale [4]. - Black Sesame Intelligence has experienced a 31% decline in stock price since its IPO, despite a positive earnings forecast, with actual performance falling short of market expectations [6]. - Yujiang, the smallest company by market capitalization at IPO, has seen its stock price increase by 188%, but its financial performance remains weak, raising concerns about its R&D investment levels [7][8]. Group 3: Financial Metrics - Crystal Technology's R&D expenditure was HKD 4.18 billion in 2024, accounting for 157% of its revenue, while Black Sesame Intelligence's R&D spending was HKD 14.35 billion, representing 302.6% of its revenue [8]. - Yujiang's R&D expenditure was only HKD 0.72 billion in 2024, which is just 19.2% of its revenue, indicating a potential deviation from the core attributes of specialized technology companies [8]. Group 4: IPO Challenges - Despite the lowered thresholds for IPOs, many companies face challenges due to weak fundamentals and unclear commercialization paths, with 9 out of 12 companies only recently meeting the commercialization revenue threshold [11]. - Companies like Xidi Zhijia and Wuyi Vision have submitted their applications again but have not made significant progress, reflecting ongoing regulatory pressures [12].

Group 1 - The core viewpoint of the articles highlights the significant shift in the Hong Kong stock market regarding the 18C specialized technology companies, with a notable decline in IPO activity and increasing challenges for these companies to commercialize successfully [1][9][11] - In 2024, the Hong Kong Stock Exchange implemented reforms that lowered the minimum market capitalization requirements for 18C companies, with commercialized companies' threshold reduced from HKD 60 billion to HKD 40 billion, and non-commercialized companies from HKD 100 billion to HKD 80 billion [1][9] - Despite the lowered thresholds, the market has seen no successful IPOs for 18C companies in 2025, with 12 companies having submitted applications but facing significant hurdles in the current market environment [9][11] Group 2 - Three listed 18C companies have engaged in active fundraising through secondary offerings, with Crystal Technology raising a total of HKD 32.2 billion, significantly exceeding its IPO fundraising scale [4] - Black Sesame Intelligence has experienced a 31% decline in stock price since its IPO, despite a positive earnings forecast, indicating a disconnect between market expectations and actual performance [6] - Yujiang, the smallest company by market capitalization at IPO, has seen its stock price increase by 188%, yet its financial performance remains weak, raising concerns about its sustainability as a specialized technology firm [7][11] Group 3 - The financial performance of the listed 18C companies shows a disparity between revenue growth and profitability, with many companies struggling to maintain a balance between innovation and short-term financial results [12] - Research and development expenditures among the companies vary significantly, with Crystal Technology and Black Sesame Intelligence investing heavily compared to Yujiang, which has reduced its R&D spending [8][12] - The overall market sentiment towards 18C companies remains cautious, as evidenced by the lack of successful IPOs and the challenges faced by companies in meeting both market expectations and regulatory requirements [9][11]

Core Viewpoint - The Hong Kong stock market has seen a significant shift in the IPO landscape for specialized technology companies, particularly those in AI, semiconductors, and autonomous driving, with no successful IPOs for 18C companies in 2025 despite previous enthusiasm in 2024 [1][9]. Group 1: Market Dynamics - In 2024, 18C specialized technology companies were highly sought after, but by 2025, the market has not seen any completed IPOs among the 12 companies that have submitted applications [1][9]. - The Hong Kong Stock Exchange implemented reforms on September 1, 2024, lowering the minimum market capitalization requirements for specialized technology companies, with commercialized companies' thresholds reduced from HKD 60 billion to HKD 40 billion [1][9]. Group 2: Company Performance - Three listed 18C companies have shown varied performance, with Crystal Technology Holdings experiencing a 93% increase since its IPO, while Black Sesame Intelligence has seen a 31% decline [2][6]. - Crystal Technology raised a total of HKD 32.2 billion through two rounds of financing, significantly exceeding its IPO fundraising [4]. - Black Sesame's performance has been hindered by a lack of clarity in its earnings report, leading to a drop in stock price post-IPO [6]. Group 3: Financial Metrics - Crystal Technology's R&D spending has been substantial, with 2024 expenditures at HKD 4.18 billion, representing 157% of its revenue [8]. - In contrast, the R&D spending of other companies like Chengdian is significantly lower, raising concerns about their innovation capabilities [8]. - The financial outlook for companies like Xi Di Zhijia shows a revenue increase of 207% but a widening loss, raising market skepticism about its sustainability [11]. Group 4: Future Outlook - Despite the lowered thresholds for IPOs, many companies still face challenges due to weak fundamentals and unclear commercialization paths [11]. - The ongoing regulatory scrutiny and market conditions may further complicate the IPO process for the remaining 12 companies [12].